Pfizer Inc. said Tuesday it had positive results in a late-stage trial of Broaden, a treatment for psoriatic arthritis in adults. The company said a first Phase 3 trial of the drug met its primary endpoints. Psoriatic arthritis is a chronic inflammatory disease, that includes symptoms such as pain and swelling of the joints, and inflation of the joints, spine, fingers and toes. An estimated 3 million people in the U.S. and Europe suffer from the disease. Separately, the U.S. Treasury announced new rules late Monday to curb corporate tax inversion that could complicate Pfizer's planned takeover of Allergan Inc. . Pfizer shares were trading up 2.6% in premarket trade.
Copyright © 2016 MarketWatch, Inc.